Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGA310
- Development stage
- Preclinical
- Lead developer
- BMG
- Modality
- Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems, Device-based Delivery → Drug Delivery Systems
- Administration
- Implant
01
Overview
SGA310 is a regenerative scaffold and biomaterial currently in preclinical development by BMG Pharma. Designed for applications in aesthetic medicine, the product serves as a structural framework to facilitate tissue regeneration and repair. As a biomaterial-based scaffold, it is intended to provide a microenvironment that supports cellular attachment and growth, though specific biological targets or chemical constituents have not been publicly disclosed by the developer.
- Other names
- SGA310 Regenerative ScaffoldSGA-310 Regenerative ScaffoldSGA 310 Regenerative Scaffold
Beyond the preview
Go deeper on SGA310.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGA310.